伊立替康联合子宫动脉介入栓塞化疗治疗宫颈癌患者的临床疗效  

Clinical efficacy of irinotecan combined with uterine artery interventional chemoembolization in the treatment of patients with cervical cancer

作　　者：邓婕 张兰兰 黄吕成 DENG Jie;ZHANG Lanlan;HUANG Lyucheng(Department of Gynecology,Baoji Hospital of Traditional Chinese Medicine,Baoji 721000,Shaanxi,China;Department of Gynecology,Baoji People’s Hospital,Baoji 721000,Shaanxi,China)

机构地区：[1]宝鸡市中医医院妇科,陕西宝鸡721000 [2]宝鸡市人民医院妇科,陕西宝鸡721000

出　　处：《癌症进展》2023年第10期1075-1077,共3页Oncology Progress

摘　　要：目的探讨伊立替康联合子宫动脉介入栓塞化疗治疗宫颈癌患者的临床疗效。方法根据治疗方法的不同将85例宫颈癌患者分为对照组(n=42,子宫动脉介入栓塞化疗)和观察组(n=43,伊立替康联合子宫动脉介入栓塞化疗)。比较两组患者的近期疗效、免疫功能指标[CD3^(+)、CD4^(+)/CD8^(+)、自然杀伤(NK)细胞、肿瘤坏死因子-α(TNF-α)]及不良反应发生率。结果观察组患者的总有效率为83.72%,高于对照组患者的61.90%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、NK细胞、TNF-α水平及CD4^(+)/CD8^(+)均高于本组治疗前,观察组患者CD3^(+)、NK细胞、TNF-α水平及CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者胃肠道反应、骨髓抑制、肝功能损伤及末梢神经毒性发生率比较,差异均无统计学意义(P﹥0.05)。结论伊立替康联合子宫动脉介入栓塞化疗治疗宫颈癌能够提高患者的近期疗效,改善患者的免疫功能,且具有一定的安全性。Objective To investigate the clinical efficacy of irinotecan combined with uterine artery interventional chemoembolization in the treatment of patients with cervical cancer.Method A total of 85 patients with cervical cancer were divided into control group(n=42,uterine artery interventional chemoembolization)and observation group(n=43,irinotecan combined with uterine artery interventional chemoembolization)according to different treatment methods.The short-term efficacy,immune function indicators[CD3^(+),CD4^(+)/CD8^(+),natural killer(NK)cell,tumor necrosis factor-α(TNF-α)],and the incidence of adverse events were compared between the two groups.Result The total effective rate of the observation group was 83.72%,higher than 61.90%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD3^(+),NK cell,TNF-α,and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,the levels of CD3^(+),NK cell,TNF-α,and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).There were no significant differences of gastrointestinal reaction,bone marrow suppression,liver function injury,and peripheral neurotoxicity between the two groups(P>0.05).Conclusion Irinotecan combined with uterine artery interventional chemoembolization in the treatment of cervical cancer could improve the short-term curative effect and immune function of patients,and have a certain degree of safety.

关 键 词：宫颈癌 伊立替康 子宫动脉介入栓塞化疗 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]